Refractory Solid Tumors Clinical Trial
Official title:
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
The Phase 1a portion of the study in subjects with advanced solid tumors will consist of a
dose escalation part followed by a dose-expansion cohort. OMP-131R10 will be administered IV
on the first day of each 14-day cycle.
Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until
progressive disease or unacceptable toxicity.
The Phase 1b portion of the study will be conducted in subjects with metastatic colorectal
cancer whose tumors have progressed after at least 1 line of therapy for metastatic disease.
Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00404508 -
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT02450136 -
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02596503 -
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT00759928 -
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06150365 -
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT01247168 -
An Open-Label, Dose-Escalation Study of AZD2461
|
Phase 1 | |
| Completed |
NCT00665990 -
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
|
Phase 1 | |
| Completed |
NCT02691793 -
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
|
Phase 4 | |
| Completed |
NCT02450149 -
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02691767 -
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
|
N/A | |
| Terminated |
NCT00664586 -
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05811975 -
KSX01-TCRT Injection Project in Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT03810742 -
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03096340 -
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02450123 -
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02383368 -
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
|
Phase 1 | |
| Completed |
NCT00394446 -
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03052205 -
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
| Recruiting |
NCT05150457 -
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
|
Phase 1 |